Inactive Instrument
Five Prime Therapeutics, Inc. Stock
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 16/4/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/4/21 | Free | Chief Financial Officer | 569,947 | 1.2238% | ||
| 16/4/21 | Issuer sale | Chief Executive Officer | 548,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 1.74B | |
| -1.59% | -3.35% | +64.49% | +98.69% | 69.54B | |
| -1.34% | -0.75% | +48.56% | +90.63% | 64.97B | |
| -8.37% | -12.43% | +0.14% | -15.42% | 25.64B | |
| -2.35% | -5.75% | -12.17% | +448.29% | 25.89B | |
| +0.30% | -0.69% | +63.18% | +11.93% | 26.51B | |
| -0.96% | +10.36% | +278.86% | +438.78% | 20.22B | |
| -0.51% | +0.23% | +33.71% | -18.02% | 19.98B | |
| -1.91% | -4.37% | +13.33% | +531.29% | 15.69B | |
| -1.47% | +0.68% | +43.67% | +145.49% | 13.49B | |
| Average | -1.82% | -1.93% | +59.31% | +192.41% | 31.33B | |
| Weighted average by Cap. | -1.92% | -1.50% | +57.15% | +152.82% |
Employees
51
